{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:19Z","timestamp":1793042779094,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jacc.2023.02.034","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T13:59:33Z","timestamp":1681739973000},"page":"1646-1658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies"],"prefix":"10.1016","volume":"81","author":[{"given":"Waqas A.","family":"Malick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna D.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.02.034_bib1","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2023.02.034_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","article-title":"Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries","volume":"129","author":"Sacks","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","article-title":"Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study","volume":"125","author":"Mora","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1161\/ATVBAHA.120.315639","article-title":"Per-particle triglyceride-rich lipoproteins imply higher myocardial infarction risk than low-density lipoproteins: Copenhagen General Population Study","volume":"41","author":"Johansen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2023.02.034_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib10","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.02.034_bib11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib12","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMe1814004","article-title":"FISHing for the miracle of eicosapentaenoic acid","volume":"380","author":"Kastelein","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib15","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.034_bib16","unstructured":"Daida H. Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013statin and eicosapentaenoic acid - RESPECT-EPA. Paper presented at: American Heart Association Scientific Sessions; Chicago, IL;\u00a02022."},{"key":"10.1016\/j.jacc.2023.02.034_bib17","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib21","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib22","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2023.02.034_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10557-021-07168-0","article-title":"Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction","volume":"35","author":"Shaik","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2023.02.034_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib26","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.02.034_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n\u22123 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","author":"The","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib29","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jacc.2023.02.034_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2022.102450","article-title":"A\u00a0biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes","volume":"182","author":"Sherratt","year":"2022","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jacc.2023.02.034_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.034_bib33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2023.02.034_bib34","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2023.02.034_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2023.02.034_bib36","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in\u00a0vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2023.02.034_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacc.2023.02.034_bib39","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2023.02.034_bib40","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib41","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib42","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jacc.2023.02.034_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2023.02.034_bib46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrin"},{"key":"10.1016\/j.jacc.2023.02.034_bib48","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib50","unstructured":"Ballantyne CM. ARO-APOC3, an investigational RNAi therapeutic, decreases serum apolipoprotein C3, triglyceride, and non-HDL-C concentrations while increasing HDL-C in patients with severe hypertriglyceridemia. Paper presented at: American Heart Association Scientific Sessions; Chicago, IL;\u00a02022."},{"key":"10.1016\/j.jacc.2023.02.034_bib51","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S]","volume":"58","author":"Haller","year":"2017","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2023.02.034_bib52","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2023.02.034_bib53","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib55","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib56","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2023.02.034_bib57","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib58","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2023.02.034_bib59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib60","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.034_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.034_bib62","article-title":"A\u00a0phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia","author":"Rosenson","year":"2021","journal-title":"American College of Cardiology"},{"key":"10.1016\/j.jacc.2023.02.034_bib63","doi-asserted-by":"crossref","unstructured":"Rosenson R, Rader DJ, Ali S, Banerjee P, McGinnis J, Pordy R. Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia. Paper presented at: European Atherosclerosis Society; Milan, Italy;\u00a02022.","DOI":"10.1016\/j.atherosclerosis.2022.06.874"},{"key":"10.1016\/j.jacc.2023.02.034_bib64","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib65","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non\u2013high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"issue":"Suppl 2):ehaa946.3331","key":"10.1016\/j.jacc.2023.02.034_bib66","article-title":"RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia","volume":"41","author":"Gerald","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.034_bib67","unstructured":"Rosenson RS. ARO-ANG3, an Investigational RNAi therapeutic, decreases serum angiopoietin-like protein 3, triglycerides, and cholesterol in patients with mixed dyslipidemia. Paper published at: American Heart Association Scientific Sessions; Chicago, IL;\u00a02022."},{"key":"10.1016\/j.jacc.2023.02.034_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ncpcardio1435","article-title":"Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies","volume":"6","author":"Rosenson","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib69","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MOL.0000000000000372","article-title":"Apolipoprotein CIII is a new player in diabetes","volume":"28","author":"Juntti-Berggren","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2023.02.034_bib70","unstructured":"Bays H KJ, Parli T, Charlton W, et\u00a0al. Prevalence of NAFLD in subjects with severe hypertriglyceridemia: initial baseline data from an ongoing phase 2 study. Paper presented at: National Lipid Association Scientific Sessions;\u00a02021."},{"key":"10.1016\/j.jacc.2023.02.034_bib71","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jacc.2023.02.034_bib72","unstructured":"Bhatt D. Results from ENTRIGUE Phase 2 trial of pegozafermin in patients with severe hypertriglyceridemia. Paper presented at: European Society of Cardiology; Barcelona, Spain;\u00a02022."},{"key":"10.1016\/j.jacc.2023.02.034_bib73","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib74","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein c-iii in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.034_bib75","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723045187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723045187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:20:05Z","timestamp":1778300405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723045187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":75,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0735109723045187"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.02.034","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}